Compare Cadila Healthcare with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs BIOCON - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE BIOCON CADILA HEALTHCARE/
BIOCON
 
P/E (TTM) x 25.2 32.4 77.7% View Chart
P/BV x 4.4 3.9 114.3% View Chart
Dividend Yield % 0.8 0.3 307.0%  

Financials

 CADILA HEALTHCARE   BIOCON
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
BIOCON
Mar-19
CADILA HEALTHCARE/
BIOCON
5-Yr Chart
Click to enlarge
High Rs352707 49.8%   
Low Rs207554 37.3%   
Sales per share (Unadj.) Rs139.291.9 151.5%  
Earnings per share (Unadj.) Rs11.816.7 70.4%  
Cash flow per share (Unadj.) Rs18.624.2 76.8%  
Dividends per share (Unadj.) Rs3.501.00 350.0%  
Dividend yield (eoy) %1.30.2 789.9%  
Book value per share (Unadj.) Rs101.4101.6 99.7%  
Shares outstanding (eoy) m1,023.74600.00 170.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.06.9 29.3%   
Avg P/E ratio x23.737.7 62.9%  
P/CF ratio (eoy) x15.026.1 57.7%  
Price / Book Value ratio x2.86.2 44.4%  
Dividend payout %29.86.0 497.1%   
Avg Mkt Cap Rs m286,033378,330 75.6%   
No. of employees `00013.46.1 218.6%   
Total wages/salary Rs m24,14511,653 207.2%   
Avg. sales/employee Rs Th10,632.78,994.3 118.2%   
Avg. wages/employee Rs Th1,801.21,900.7 94.8%   
Avg. net profit/employee Rs Th898.51,635.3 54.9%   
INCOME DATA
Net Sales Rs m142,53155,144 258.5%  
Other income Rs m1,1391,444 78.9%   
Total revenues Rs m143,67056,588 253.9%   
Gross profit Rs m24,19815,883 152.4%  
Depreciation Rs m6,9654,478 155.5%   
Interest Rs m3,418709 482.1%   
Profit before tax Rs m14,95412,140 123.2%   
Minority Interest Rs m2889 3,200.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1982,123 150.6%   
Profit after tax Rs m12,04410,026 120.1%  
Gross profit margin %17.028.8 58.9%  
Effective tax rate %21.417.5 122.3%   
Net profit margin %8.518.2 46.5%  
BALANCE SHEET DATA
Current assets Rs m87,15448,228 180.7%   
Current liabilities Rs m82,69430,376 272.2%   
Net working cap to sales %3.132.4 9.7%  
Current ratio x1.11.6 66.4%  
Inventory Days Days7168 104.6%  
Debtors Days Days9486 109.7%  
Net fixed assets Rs m133,23664,130 207.8%   
Share capital Rs m1,0243,000 34.1%   
"Free" reserves Rs m102,73357,980 177.2%   
Net worth Rs m103,75760,980 170.1%   
Long term debt Rs m32,14615,766 203.9%   
Total assets Rs m236,866121,924 194.3%  
Interest coverage x5.418.1 29.7%   
Debt to equity ratio x0.30.3 119.8%  
Sales to assets ratio x0.60.5 133.0%   
Return on assets %6.58.8 74.1%  
Return on equity %11.616.4 70.6%  
Return on capital %13.716.8 82.0%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m52,75215,506 340.2%   
Fx outflow Rs m14,50410,399 139.5%   
Net fx Rs m38,2485,107 748.9%   
CASH FLOW
From Operations Rs m25,05411,546 217.0%  
From Investments Rs m-10,123-7,138 141.8%  
From Financial Activity Rs m-10,942-2,417 452.7%  
Net Cashflow Rs m3,9892,103 189.7%  

Share Holding

Indian Promoters % 74.8 40.4 185.1%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 8.3 8.4 98.8%  
FIIs % 5.9 10.7 55.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 19.9 55.3%  
Shareholders   44,069 109,995 40.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 500 Points; Grasim Industries & HDFC Bank Top Gainers(09:30 am)

Asian share markets are trading on a mixed note tracking a mixed Wall Street session following a big downturn in tech shares.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

Charge Your Portfolio with this Smallcap Proxy Play on India's EV Revolution(Profit Hunter)

Mar 5, 2021

This could be the biggest wealth creator of the decade.

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Mar 9, 2021 10:04 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - NEULAND LABS COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS